Compare prices and buy VIP from 24 research peptide vendors - also called suppliers or sources. Updated daily.
A 28-amino-acid neuropeptide with an amidated C-terminus (vasoactive intestinal peptide, CAS 40077-57-4, C147H238N44O42S), a member of the secretin and glucagon family, widely distributed in the central and peripheral nervous systems. It acts on the VPAC1 and VPAC2 class B G-protein-coupled receptors, which also respond to PACAP, and is studied for its roles in vasodilation, immune regulation and circadian timing. Its plasma half-life in people is measured in minutes. Developed as a drug under the name aviptadil, it has been tested in pulmonary hypertension, sarcoidosis and COVID-19 respiratory failure. Neither VIP nor aviptadil is FDA-approved.
For research purposes only. Not medical advice.
Vasoactive intestinal peptide is a 28-residue neuropeptide. No FDA-approved product contains it, and in the NIH's placebo-controlled TESICO trial in COVID-19 respiratory failure it did not improve recovery. Sami Said and Viktor Mutt isolated it from hog small intestine and reported its vasodilator activity in Science in 1970.
The human and porcine sequences are identical, and the C-terminal asparagine is amidated. FDA's substance registry lists the peptide under its international nonproprietary name, aviptadil (UNII A67JUW790C), with CAS 40077-57-4 as the primary registry number. The amidated peptide's formula is C147H238N44O42S. PubChem's main record under that CAS number draws the C-terminus as a free acid instead, giving C147H237N43O43S.
VIP belongs to the secretin and glucagon family, alongside PACAP, GHRH, GIP and the glucagon-like peptides. PACAP, isolated from ovine hypothalamus in 1989, shares 68 percent of VIP's N-terminal sequence (Miyata, Biochemical and Biophysical Research Communications). In healthy volunteers, plasma VIP falls with a half-time of about one minute once an intravenous infusion stops (Domschke, Gut, 1978).
VIP signals through two class B G protein-coupled receptors, VPAC1 and VPAC2, both of which also respond to PACAP with high affinity. A third receptor, PAC1, is selective for PACAP (Harmar, British Journal of Pharmacology, 2012). The same review lists roles in circadian timing, immunity and inflammation, insulin secretion, and co-transmission in autonomic and sensory nerves. Mice lacking VPAC2 cannot sustain normal circadian rest and activity rhythms and lose rhythmic clock-gene expression in the suprachiasmatic nuclei (Harmar, Cell, 2002).
Results split by design. The uncontrolled studies reported improvements. Of the placebo-controlled trials below, an 80-patient inhaled trial met its primary endpoint and the three others missed theirs.
No FDA-approved drug contains VIP, and drugsfda returns no application under VIP or aviptadil as of October 2026. Vasoactive intestinal peptide is in Category 1 of FDA's 503A bulk drug substance nominations, the substances under evaluation (list updated May 14, 2026). FDA's interim policy for that category is not to act against compounders who meet its conditions while the review continues. VIP appears in neither table of FDA's Category 2 safety-risk page, and a full-text search of FDA's warning letters returns none naming vasoactive intestinal peptide or aviptadil.
Drug development ran under the name aviptadil, from an erectile-dysfunction injection combined with phentolamine to a COVID-19 program whose emergency use request FDA declined in November 2021, and is covered on the Aviptadil page. FDA orphan designations for the molecule in acute respiratory distress syndrome (2001), pulmonary arterial hypertension (2005) and sarcoidosis (2020) have produced no approval.
Yes. Aviptadil is the international nonproprietary name for synthetic vasoactive intestinal peptide, and FDA's substance registry files both names under one record with the same 28-residue sequence, the same amidated C-terminus and CAS 40077-57-4. The difference is commercial and regulatory. Drug developers used the name aviptadil for clinical programs in erectile dysfunction, pulmonary hypertension, sarcoidosis and COVID-19, while research vendors mostly sell the peptide as VIP. PeptideScouter indexes the two names as separate rows because vendors list and price them as different products, so a VIP listing is compared with other VIP listings.
Results depend on the trial. In the NIH's TESICO trial of critically ill patients with COVID-19 respiratory failure, published in Lancet Respiratory Medicine in 2023, intravenous aviptadil did not improve the 90-day recovery outcome in the modified intention-to-treat population of 461 (odds ratio 1.11), and 90-day mortality was 38 percent against 36 percent on placebo. An earlier 196-patient intravenous trial sponsored by NRx Pharmaceuticals missed its day-60 primary endpoint and reported a survival difference only as a secondary endpoint. An 80-patient double-blind trial of inhaled aviptadil in hospitalized COVID-19 pneumonia reported a shorter time to discharge, its primary endpoint (Medical Principles and Practice, 2025). A 56-patient Phase 2 trial in pulmonary arterial hypertension found no reduction in pulmonary vascular resistance over 12 weeks.
Vasoactive intestinal peptide is in Category 1 of FDA's list of bulk drug substances nominated for the 503A compounding bulks list, the group the agency describes as under evaluation, in the version updated May 14, 2026. For Category 1 substances, FDA says it does not intend to take action against compounders who meet the conditions of its interim guidance while it decides whether to add the substance to the list. That is an enforcement policy pending review, and it is neither an approval nor a safety finding. No FDA-approved drug contains VIP or aviptadil, and as of October 2026 VIP is not among the five substances FDA has named for its next Pharmacy Compounding Advisory Committee meeting.
Minutes. In four healthy volunteers given intravenous infusions, plasma VIP fell with an average half-time of about one minute once the infusion stopped, according to Domschke and colleagues in Gut in 1978. A Danish study in six volunteers measured elimination in two phases, with half-lives of 2 and 21 minutes (Holm-Bentzen and colleagues, Scandinavian Journal of Gastroenterology, 1981). The Domschke group concluded that their data did not support a role for VIP as a circulating hormone under physiological conditions. Clinical programs delivered it by intravenous infusion or by inhalation.
One uncontrolled study. The main published report is an open-label series of 20 patients given a VIP nasal spray, published by Shoemaker, House and Ryan in the journal Health in 2013. It had no concurrent control group and compared its patients with previously published cohorts. ClinicalTrials.gov lists no registered study of chronic inflammatory response syndrome as of October 2026, and no FDA-approved product contains VIP for this or any other use. FDA's Category 1 listing for VIP is an evaluation in progress and carries no finding that the peptide is safe or effective for any condition.
VIP is sold by 24 research peptide vendors indexed on PeptideScouter, with 32 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
21 of the 24 indexed vendors currently have VIP in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Peppy and Me currently lists VIP at $3.50/mg, the lowest listed price across 24 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.53/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 24 vendors listing VIP publish a PeptideScouter code, worth 10% to 50% off. Applied, the lowest effective price falls from $2.81/mg listed to $2.53/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
VIP ranges from $2.81/mg to $12.00/mg across 32 listings from 24 research peptide vendors, normalized to USD per milligram and refreshed daily.
24 research peptide vendors currently list VIP on PeptideScouter, with 21 in stock right now. We track 32 listings across size and kit variants.
VIP's CAS Registry Number is 40077-57-4. It is also sold as Vasoactive Intestinal Peptide, VIP (Vasoactive Intestinal Peptide).
